Reducing Risk of Stroke and DementIa In patientS With COVert cERebrovascular Disease (DISCOVER)
Reducing Risk of Stroke and DementIa In patientS With COVert cERebrovascular Disease: a Pilot and Development Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: William Whiteley
- Phone Number: +44(131) 4659602
- Email: william.whiteley@ed.ac.uk
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
People who, at the time the letter is prepared or are identified by a clinician
- Age ≥ 65 years
Have no known history of:
- Stroke or TIA
- Dementia
- Parkinson's disease
- Multiple sclerosis
- Metastatic cancer (or non-meningioma brain tumour).
A CT or MRI scan report ≤5 years before study start date with of one or more of:
- Cerebral small vessel disease
- Deep old ischaemic stroke
- Cortical old ischaemic stroke
Exclusion Criteria:
- Text of brain scan report unreadable
- Do not consent to take part in study procedures
- Unable to consent
- Unable to communicate by email, letter or telephone through language, speech disability or lack of address
- Unlikely to survive one year past enrolment in judgement of the study investigator
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Speech samples
Time Frame: At 3, 6 and 12 months following enrolment
|
Speech will be measured at assessment, in collaboration with the NeuroCARE Clinical and Digital Measures Module (22/SS/0010 IRAS No. 310885).
|
At 3, 6 and 12 months following enrolment
|
|
Vascular events
Time Frame: At 3, 6 and 12 months following enrolment
|
At each assessment the investigators will ask about dementia, mild cognitive impairment and stroke symptoms.
|
At 3, 6 and 12 months following enrolment
|
|
Functional scores
Time Frame: At 3, 6 and 12 months following enrolment
|
The investigators will measure day-to-day function with the Bristol Activities of Daily Living Scale, which is a 20-item assessment of daily living abilities for dementia.
Each activity has 5 statement options (a - e) which refer to a different level of ability.
|
At 3, 6 and 12 months following enrolment
|
|
Cognitive scores
Time Frame: At 3, 6 and 12 months following enrolment
|
The investigators will measure concerns or anxiety about covert cerebrovascular disease using the Montreal Cognitive Assessment.
It is a 10-minute test that assesses seven areas of cognition for a total possible score of 30 points.
A score of 25 or less is indicative of cognitive impairment.
|
At 3, 6 and 12 months following enrolment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Nervous System Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Myopathies, Structural, Congenital
- Myopathy, Central Core
- Public Health
- Environment and Public Health
- Health Services
- Health Care Facilities Workforce and Services
- Rehabilitation
- Health Status
- Demography
- Epidemiologic Measurements
- Activities of Daily Living
- Functional Status
Other Study ID Numbers
Other Study ID Numbers
- AC25041
- HIPS/23/02 (Other Grant/Funding Number: Chief Scientist's Office, Scotland, UK)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.